Syntegon and Telstar officially join forces

The successful closing of the Telstar acquisition by Syntegon sees the business significantly expand its pharmaceutical liquid filling offering.

Following regulatory approval, Syntegon and Azbil Corporation have officially closed the acquisition of Telstar by Syntegon. The Telstar workforce will now join the Syntegon team in the Pharma Liquid Business Unit. With the joint offering of fill-finish equipment, isolator systems, freeze-dryers, loading and unloading systems as well as further upstream and downstream equipment, customers now have access to a seamless technology and service portfolio for the production of antibiotics, vaccines, or biologics. 

Strengthening strategic growth 

“Syntegon is world market leader in liquid vial filling and isolator systems. Together with Telstar, we will further enhance our portfolio of innovative technologies and sustainable solutions, strengthen our strategic growth, and expand our global reach,” says Torsten Türling, CEO of the Syntegon Group. “We received highly positive customer feedback and several inquiries for our joint offering following the acquisition announcement in June. This clearly shows that we are on the right track to becoming the go-to partner for seamless solutions from a single source.” 

Leveraging joint expertise 

“We are very much looking forward to leveraging our joint expertise for the benefits of our existing and new customers,” says Jordi Puig, Managing Director of Telstar. “By using the synergies of a strong team, we can offer truly seamless line solutions and streamlined processes with one face to the customer. This way, we will support them even better in achieving long-term stability of their pharmaceuticals and fast time to market.”  

Telstar, headquartered in Terrassa (Barcelona), Spain, has four production plants, six technology centres and 10 consultancy and engineering services centres, and commercial offices all over the world. By combining these capabilities with Syntegon’s global reach, both companies are now in an even better position to offer both pharmaceutical manufacturers and Contract Manufacturing Organisations complete line solutions. Moreover, the joint service network will be expanded significantly, adding geographical coverage, proximity, and application expertise.